Olson L G, Hensley M J, Saunders N A
J Appl Physiol Respir Environ Exerc Physiol. 1982 Sep;53(3):637-43. doi: 10.1152/jappl.1982.53.3.637.
The effect of the dopamine-receptor blocking agent prochlorperazine on the ventilatory response to hypercapnic hypoxia was studied in six healthy adults. Repeated episodes of transient hypoxia were induced at the mixed venous PCO2 level by a nonrebreathing technique in five males and one female before and after an intravenous bolus injection of prochlorperazine mesylate (12.5 mg = 10 mg base). The ventilatory response to CO2 was also studied before and after drug administration. Prochlorperazine produced a modest (15%) increase in resting ventilation (P less than 0.05) but a marked increase in the ventilatory response to asphyxia such that the group mean response was double the control value [2.0 +/- 0.7 vs. 4.2 +/- 1.5 l . min-1 . % arterial O2 saturation (%SaO2); P less than 0.001]. Two-thirds of this change in ventilatory response was due to an increase in frequency response to hypoxia (0.34 +/- 0.20 vs. 0.81 +/- 0.52 breaths . min-1 . %SaO2; P less than 0.001). The position of the ventilatory response line, as judged by the computed ventilation at 95% SaO2, was increased by prochlorperazine (22.2 +/- 9.6 vs. 35.9 +/- 10.9 l . min-1; P less than 0.01) due to an increase in both tidal volume (P less than 0.05) and frequency of breathing (P less than 0.0125). The ventilatory response to CO2 was unchanged by drug injection. In separate experiments prochlorperazine was shown to 1) increase the ventilatory response to steady-state eucapnic hypoxia (P less than 0.01) demonstrating that the drug effect was not dependent on either the presence of hypercapnia or rapidly changing states of arterial oxygenation; and 2) reverse the depressant effect of intravenously infused dopamine hydrochloride (5 micrograms . kg-1 . min-1) on the ventilatory response to transient asphyxia (P less than 0.01). We conclude that prochlorperazine augments hypoxic responsiveness in humans. The mechanism may be blockade of dopaminergic receptors that modulate carotid body discharge.
在六名健康成年人中研究了多巴胺受体阻断剂丙氯拉嗪对高碳酸血症性低氧通气反应的影响。在静脉推注甲磺酸丙氯拉嗪(12.5毫克=10毫克碱基)之前和之后,通过无重复呼吸技术在五名男性和一名女性的混合静脉血二氧化碳分压水平诱导反复短暂性低氧发作。还在给药前后研究了对二氧化碳的通气反应。丙氯拉嗪使静息通气适度增加(15%)(P<0.05),但对窒息的通气反应显著增加,以至于组平均反应是对照值的两倍[2.0±0.7对4.2±1.5升·分钟-1·%动脉血氧饱和度(%SaO2);P<0.001]。通气反应的这种变化的三分之二归因于对低氧的频率反应增加(0.34±0.20对0.81±0.52次呼吸·分钟-1·%SaO2;P<0.001)。根据在95%SaO2时计算的通气量判断,丙氯拉嗪使通气反应线的位置增加(22.2±9.6对35.9±10.9升·分钟-1;P<0.01),这是由于潮气量增加(P<0.05)和呼吸频率增加(P<0.0125)。药物注射后对二氧化碳的通气反应未改变。在单独的实验中,丙氯拉嗪被证明:1)增加对稳态等碳酸血症性低氧的通气反应(P<0.01),表明药物作用不依赖于高碳酸血症的存在或动脉氧合的快速变化状态;2)逆转静脉输注盐酸多巴胺(5微克·千克-1·分钟-1)对短暂窒息通气反应的抑制作用(P<0.01)。我们得出结论,丙氯拉嗪增强了人类的低氧反应性。其机制可能是阻断调节颈动脉体放电的多巴胺能受体。